Over the past 2 decades, liver transplantation (LT) has undergone a profound transformation in different fields. In particular, once characterized by massive blood product utilization, LT is now characterized by restrictive, goal-directed transfusion strategies rooted in patient blood management (PBM) principles. At the same time, indications have expanded, with transplant oncology redefining the role of LT in selected patients beyond traditional criteria. Together, these advances have compelled anesthesiologists and surgeons to adopt more precise, evidence-based approaches. In particular, in LT for hepatocellular carcinoma (HCC), few questions have been as persistent and as consequential as how to reconcile effective blood conservation with uncompromised oncologic safety. Although intraoperative cell salvage (IOCS) has become a standard of care for several surgical procedures, its liberal use in oncology surgery remains a matter of debate due persisting concerns regarding the theoretical risk of reinfusing malignant cells. At the heart of this debate lies a pivotal yet often underemphasized principle: leukocyte depletion filters (LDF) and irradiation of salvaged blood components represent 2 distinct and complementary strategies to prevent the reinfusion of malignant cells during autotransfusion in oncologic surgery: LDF acting through physical removal of tumor cells, and irradiation through irreversible biological inactivation of any residual nucleated, potentially tumorigenic elements.

Against this backdrop, the study from Liège published in this issue of Transplantation offers a timely contribution: it challenges the long-standing practice of using LDF, traditionally used to reduce tumor cell contamination of reinfused blood, and proposes irradiation of salvaged red blood cells as a standalone strategy during IOCS.

The authors present a retrospective, single-center cohort analysis spanning more than a decade, evaluating the oncologic safety of autotransfusion of irradiated red blood cells, without the use of LDF, during LT for HCC. Their primary finding is clear: this approach was not associated with an increased risk of HCC recurrence or reduced survival. With a median follow-up approaching 10 y, recurrence-free survival and overall survival were comparable between patients who received irradiated autotransfusion and those who did not. Importantly, these findings persisted after adjustment for key prognostic variables, including MELD score, tumor burden, and microvascular invasion. This study reinforces an evolving paradigm within PBM: minimizing exposure to allogeneic transfusion without compromising clinical outcomes.